Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why Ligand Pharmaceuticals Plummeted 16% Today

By Brian Orelli, PhD - Updated Apr 19, 2019 at 7:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

When Citron speaks, investors listen -- but should they?

What happened

Shares of Ligand Pharmaceuticals ( LGND 1.14% ) closed down 16% to $110.05 on Wednesday, having been down as much as 25%, after Citron Research released a report arguing that the drug developer is only worth $35 per share.

Citron notoriously shorts stocks prior to writing negative reports, so investors should take that into account while evaluating the value of the research.

A variety of pills atop $100 bills.

Image source: Getty Images.

So what

Ligand Pharmaceuticals' business model is to collect royalties and milestone payments from compounds and intellectual property that it licenses to drug developers.

Most of Citron's report focuses on Ligand's potential milestone payments, noting that Viking Therapeutics accounts for 50% of the potential milestone payments, while Vernalis accounts for another 12%.

The thing is -- and every drug company investor should know this -- looking at milestone payments is a terrible way to value a drug development deal. For competitive reasons, most companies don't disclose the triggers for milestones -- is it start of phase 2? Positive phase 3? FDA approval? Sales of $200 million annually? $1 billion? -- and they also don't disclose how much of the total is allocated to each milestone, although sometimes companies will break out "development" milestones from "commercial" milestones, so at least investors can figure out the relative individual timing of the two blocks.

Investors shouldn't be focused on potential milestone payments to Ligand because there's no way to accurately determine when they'll come in and how large they'll be.

Now what

What investors should be focused on are royalties that Ligand will get on its licensed drugs. There's still some uncertainty, as royalties are often tiered, but the minimum levels are generally known. Many of the drugs Ligand has partnered on are in phase 2 or earlier development, so the potential royalties on sales are years away, but they'll also come in year after year, while milestone payments are one-time payments (although each deal typically has multiple milestone payments).

Whether the current and potential royalties justify Ligand's $2.3 billion market cap is up for debate, depending on how likely you think it is that the drugs will be approved and their potential peak sales, but given the unknowns with milestone payments, investors shouldn't be penciling them into their valuation models, and therefore Citron's argument that a large chunk comes from two companies shouldn't concern investors too much.

Check out the latest Ligand Pharmaceuticals earnings call transcript.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ligand Pharmaceuticals Incorporated Stock Quote
Ligand Pharmaceuticals Incorporated
LGND
$157.01 (1.14%) $1.77

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
673%
 
S&P 500 Returns
142%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.